Skip to main content

Table 3 NF-κB staining and ovarian tumor survival outcomes, the VUMC TROC

From: Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

 

Progression-free survival (PFS)

Overall survival (OS)

Unadjusted

Adjusted a

Unadjusted

Adjusted a

Compartmentalized staining

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

p52: Non-canonical NF-κB transcription factor

 Cytoplasmic staining

2.15 (1.55–2.98)

< 0.001

1.54 (1.09–2.18)

0.015

1.98 (1.42–2.75)

< 0.001

1.53 (1.07–2.18)

0.019

 Nuclear staining

2.05 (1.46–2.86)

< 0.001

1.67 (1.15–2.42)

0.006

1.82 (1.30–2.55)

< 0.001

1.49 (1.02–2.17)

0.041

p65: Canonical NF-κB transcription factor

 Cytoplasmic staining

1.02 (0.75–1.40)

0.885

1.05 (0.75–1.47)

0.776

1.08 (0.79–1.48)

0.636

1.13 (0.81–1.57)

0.472

 Nuclear staining

1.40 (1.02–1.92)

0.037

1.20 (0.85–1.69)

0.300

1.37 (1.00–1.89)

0.052

1.31 (0.93–1.84)

0.124

Total staining

 Independent models

  p52: Cytoplasmic or Nuclear

1.78 (1.28–2.47)

< 0.001

1.53 (1.08–2.19)

0.018

1.73 (1.24–2.41)

0.001

1.61 (1.12–2.33)

0.011

  p65: Cytoplasmic or Nuclear

1.38 (0.99–1.92)

0.054

1.27 (0.89–1.81)

0.186

1.38 (0.99–1.92)

0.059

1.31 (0.92–1.88)

0.138

 Mutually adjusted models b

  p52: Cytoplasmic or Nuclear

1.70 (1.21–2.38)

0.002

1.49 (1.04–2.14)

0.030

1.64 (1.16–2.32)

0.005

1.57 (1.08–2.27)

0.018

  p65: Cytoplasmic or Nuclear

1.24 (0.88–1.73)

0.217

1.18 (0.82–1.71)

0.348

1.22 (0.86–1.72)

0.260

1.23 (0.85–1.77)

0.265

Among high-grade serous cases c

 Independent models

  p52: Cytoplasmic or Nuclear

1.79 (1.17–2.75)

0.007

1.68 (1.08–2.62)

0.020

1.65 (1.07–2.56)

0.024

1.61 (1.03–2.53)

0.038

  p65: Cytoplasmic or Nuclear

0.90 (0.58–1.36)

0.606

1.14 (0.74–1.76)

0.551

1.02 (0.67–1.57)

0.921

1.16 (0.75–1.81)

0.499

 Mutually adjusted models b

  p52: Cytoplasmic or Nuclear

1.91 (1.23–2.96)

0.004

1.68 (1.07–2.62)

0.024

1.70 (1.09–2.66)

0.021

1.59 (1.01–2.52)

0.045

  p65: Cytoplasmic or Nuclear

0.76 (0.49–1.18)

0.223

1.03 (0.66–1.61)

0.899

0.89 (0.57–1.39)

0.612

1.09 (0.69–1.69)

0.719

  1. a Adjusted for age at diagnosis (continuous), stage (early, late), histologic subtype (serous, endometrioid and clear cell, mucinous and other), grade (borderline, low, high), and platinum and/or taxane chemotherapy (yes, no or unknown)
  2. b Mutually adjusted models include both p52 and p65 (cytoplasmic or nuclear staining)
  3. c Model does not include adjustment for grade or histologic subtype because only high-grade serous cases (N = 118) were included in this analysis